| Analyst: | Veljee, Tahira | EPS
Est. Accuracy: | Not Avl.
| | Broker: | Virtua Research | Recommendation
Performance: | Not Avl.
|
|
| Stocks Covered
| |
Alkermes Inc (ALKS), Alnylam Pharmaceuticals Inc (ALNY), Biomarin Pharmaceutical Inc (BMRN), Cytrx Corp (CYTR), Cytori Therapeutics Inc (CYTX), Emergent Biosolutions Inc (EBS), Enzon Pharmaceuticals Inc (ENZN), Hemispherx Biopharma, Inc. (HEB), Immunomedics Incorporated (IMMU), Isis Pharmaceuticals Inc (ISIS), Molecular Insight Pharma Inc (MIPI), Momenta Pharmaceuticals Inc (MNTA), Nabi Biopharmaceuticals (NABI), Osi Pharmaceuticals Inc (OSIP), Poniard Pharmaceuticals Inc (PARD), Peregrine Pharmaceutical (PPHM), Regeneron Pharmaceuticals (REGN), Seattle Genetics Inc (SGEN), Stemcells Inc (STEM), Theravance Inc (THRX), Vertex Pharmaceuticals Inc (VRTX)
|
| | |
|